Risk of breakthrough SARS‐CoV‐2 infection and clinical outcomes among vaccinated patients with type 2 diabetes
Bea S, Choi A, Kim JH, et al.
Diabetes Obes Metab. Pub. online 13 Jun 2023.
Leggi
Breaking news
Potential value of identifying type 2 diabetes subgroups for guiding intensive treatment: a comparison of novel data-driven clustering with risk-driven subgroups
Li X, van Giessen A, Altunkaya J, et al.
Diabetes Care. 2023;46(7):1395-1403.
Leggi
The association between body weight indices, behavioural factors, and type 2 diabetes mellitus in Africa: a systematic review and meta-analysis of population-based epidemiological studies
Issaka A, Paradies Y, Cameron AJ, Stevenson C
NMCD. Pub. online 19 Jun 2023.
Leggi
Cholesterol crystal formation is a unifying pathogenic mechanism in the development of diabetic retinopathy
Hammer SS, Dorweiler TF, McFarland D, et al.
Diabetologia. Pub. online 14 Jun 2023.
Leggi
Evaluation of the effects of ezetimibe on albuminuria and kidney fat in individuals with type 2 diabetes and chronic kidney disease
Heinrich NS, Pedersen RP, Vestergaard MB, et al.
Diabetes Obes Metab. Pub. online 6 Jun 2023.
Leggi
Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial
Pieber TR, Arfelt KN, Cailleteau R, et al.
Diabetologia. Pub. online 13 Jun 2023.
Leggi
Diabetes, fasting blood glucose and the efficacy of remote ischaemic conditioning: a secondary analysis of the RICAMIS trial
Zhang YN, Dai YJ, Cui Y, et al.
Diabetes Obes Metab. Pub. online 8 Jun 2023.
Leggi
The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes
Ceriello A, Lucisano G, Prattichizzo F, La Grotta R, Frigé C, De Cosmo S, Di Bartolo P, Di Cianni G, Fioretto P, Giorda CB, Pontremoli R, Russo G, Viazzi F, Nicolucci A
The Lancet Regional Health-Europe. Pub. online 12 Jun 2023.
Leggi
Orforglipron (LY3502970), a novel, oral non‐peptide glucagon‐like peptide‐1 receptor agonist: A Phase 1b, multicentre, blinded, placebo‐controlled, randomized, multiple‐ascending‐dose study in people with type 2 diabetes
Pratt E, Ma X, Liu R, et al.
Diabetes Obes Metab. Pub. online 1 Jun 2023.
Leggi
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in Diabetic patients with Acute Myocardial Infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT Registry
Paolisso P, Bergamaschi L, Cesaro A, et al.
Diabetes Res Clin Pract. 2023;110766.
Leggi